Cross-talk between SARS-CoV-2 infection and the insulin/IGF signaling pathway: implications for metabolic diseases in COVID-19 and for post-acute sequelae of SARS-CoV-2 infection

The pandemic of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection that causes coronavirus disease 2019 (COVID-19) has had a devastating impact on humanity. SARS-CoV-2 infection affects the function of several human tissues including metabolically active and endocrine tissues to induce several metabolic abnormalities such as insulin resistance and diabetes [1 –4]. However, the mechanisms underlying how SARS-CoV-2 induces metabolic disease remain to be fully elucidated. In a study published in Metabolism, Shin et al showed that SARS-CoV-2 infection impairs insulin-like growth factor 1 (IGF)/insulin signaling pathway in respiratory, metabolic and endocri ne cells and tissues [5].
Source: Metabolism - Clinical and Experimental - Category: Biomedical Science Authors: Tags: Editorial Source Type: research